Fulcrum Therapeutics (FULC) EBIAT (2020 - 2025)
Historic EBIAT for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$19.6 million.
- Fulcrum Therapeutics' EBIAT rose 968.38% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.2 million, marking a year-over-year decrease of 31955.56%. This contributed to the annual value of -$9.7 million for FY2024, which is 9000.87% up from last year.
- Latest data reveals that Fulcrum Therapeutics reported EBIAT of -$19.6 million as of Q3 2025, which was up 968.38% from -$17.3 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' EBIAT ranged from a high of $55.4 million in Q2 2024 and a low of -$34.1 million during Q2 2022
- For the 5-year period, Fulcrum Therapeutics' EBIAT averaged around -$18.6 million, with its median value being -$23.6 million (2021).
- As far as peak fluctuations go, Fulcrum Therapeutics' EBIAT skyrocketed by 33297.73% in 2024, and later plummeted by 13121.51% in 2025.
- Over the past 5 years, Fulcrum Therapeutics' EBIAT (Quarter) stood at -$23.5 million in 2021, then dropped by 11.29% to -$26.1 million in 2022, then grew by 5.28% to -$24.8 million in 2023, then surged by 33.07% to -$16.6 million in 2024, then fell by 18.27% to -$19.6 million in 2025.
- Its EBIAT was -$19.6 million in Q3 2025, compared to -$17.3 million in Q2 2025 and -$16.6 million in Q4 2024.